Approaches of cancer immunotherapy have recently been boosted by the discovery that immune checkpoint-specific monoclonal antibodies (ICmAbs), such as antibodies against CTLA-4, PD-1, and PD-L1, can rescue the adaptive cellular immune response, mostly CTL, kept at bay by the tumor [63,64]. The gene discussed is CTLA4; the disease is neoplasm.